Argus
•
Oct 14, 2026
HRMY: Lowering target price to $41.00
Summary
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs.
Upgrade to begin using premium research reports and get so much more.
Exclusive reports, detailed company profiles, and best-in-class trade insights to take your portfolio to the next level
UpgradeRelated Reports
ARQT: Lowering target price to $33.00
Oct 28, 2026
•
ARQT
KRYS: Lowering target price to $353.00
Oct 28, 2026
•
KRYS
ARQT: Raising target price to $34.00
Oct 21, 2026
•
ARQT
KRYS: Raising target price to $358.00
Oct 21, 2026
•
KRYS
ARQT: Raising target price to $27.00
Oct 14, 2026
•
ARQT
